On 2nd July, the European Commission launched the EU’s new Life Sciences Strategy, which objective is to transform scientific discoveries into tangible health benefits. It commits significant funding to accelerate the development and access to breakthrough treatments like advanced therapies. A central pillar is the promotion of multi-country clinical trials and streamlined, innovation-friendly regulation via a proposed EU Biotech Act and regulatory sandboxes, designed to reduce fragmentation and bring treatments to patients more swiftly across the EU. Crucially, the strategy also emphasises using rare diseases as a guiding focus. The Strategy also aims to integrate patient voices into governance frameworks like the new Life Science Coordination Group and ensure equitable access via cross‑border trial infrastructure and procurement.

Next Steps

The EU Life Sciences Strategy is expected to be adopted by the Council of the EU in autumn